Diadema Partners’s AstraZeneca AZN Stock Holding History

Diadema Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-15,000	Closed	-$3.93M	–	113
2024 Q4	$3.93M	Buy	+15,000	New	+$2.1M	1.69%	16

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Diadema Partners's AZN Position: Q1 2025 in Review

Diadema Partners sold out of AstraZeneca (AZN) in Q1 2025, closing a stake of 15,000 shares — an estimated $3.93M sold.

Diadema Partners first reported a position in AZN in Q4 2024 and held it in 1 quarter. The position peaked at $3.93M in Q4 2024. 1,249 funds tracked by Wall St. Rank hold AZN as of Q1 2025.

Diadema Partners reported no remaining AstraZeneca position as of Q1 2025 after selling out during the quarter.
Diadema Partners sold 15,000 AstraZeneca shares in Q1 2025, an estimated $3.93M.
Diadema Partners first reported a position in AstraZeneca in Q4 2024 and held it in 1 quarter.
Diadema Partners's AstraZeneca position peaked at $3.93M in Q4 2024.
1,249 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2025.

Based on Diadema Partners's 13F filing for Q1 2025, filed 15 May 2025.